Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RABITO
2024-515602-34-01Phase 4Authorised
- Sponsor
- Rijnstate
- Start
- Jan 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 4, randomised trial of iodine-131 in hyperthyroidism, Toxic adenoma and Solitary Toxic Adenoma (STA) (2 arms), sponsored by Rijnstate. Primary endpoint: Cumulative incidence of irreversible hypothyroidism in the first year after intervention. Planned start Jan 2025; status: authorised.
02
Drugs
iodine-131
03
Conditions
hyperthyroidismToxic adenomaSolitary Toxic Adenoma (STA)
Beyond the preview
Go deeper on 2024-515602-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515602-34-01.